Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Long-Term Investments: 2017-2024

Historic Long-Term Investments for Aclaris Therapeutics (ACRS) over the last 5 years, with Dec 2024 value amounting to $90.3 million.

  • Aclaris Therapeutics' Long-Term Investments rose 55.96% to $71.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $71.3 million, marking a year-over-year increase of 55.96%. This contributed to the annual value of $90.3 million for FY2024, which is 43.86% up from last year.
  • Per Aclaris Therapeutics' latest filing, its Long-Term Investments stood at $90.3 million for FY2024, which was up 43.86% from $62.8 million recorded in FY2023.
  • Aclaris Therapeutics' Long-Term Investments' 5-year high stood at $90.3 million during FY2024, with a 5-year trough of $12.2 million in FY2022.
  • Over the past 3 years, Aclaris Therapeutics' median Long-Term Investments value was $62.8 million (recorded in 2023), while the average stood at $55.1 million.
  • Per our database at Business Quant, Aclaris Therapeutics' Long-Term Investments plummeted by 64.25% in 2022 and then spiked by 412.75% in 2023.
  • Aclaris Therapeutics' Long-Term Investments (Yearly) stood at $34.2 million in 2021, then slumped by 64.25% to $12.2 million in 2022, then soared by 412.75% to $62.8 million in 2023, then spiked by 43.86% to $90.3 million in 2024.